Japan Medical Association Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2007
NCT00504348
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

tacrolimus (prograf) (1 trial)

Drugs in Phase 2 Trials (1)

habekacin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dermatomyositis (Phase 3)

Lung Diseases, Interstitial (Phase 3)

Muscular Dystrophies (Phase 2)

Muscular Dystrophy, Duchenne (Phase 2)

Pneumonia (Phase 3)

Polymyositis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2